Experience of safety monitoring in the context of a prospective observational study of artemetherlumefantrine in rural Tanzania: lessons learned for pharmacovigilance reporting 
Objectives
To identify and implement strategies that help meet safety monitoring requirements in the context of an observational study for artemether-lumefantrine (AL) administered as first-line treatment for uncomplicated malaria in rural Tanzania.
Methods
Pharmacovigilance procedures were developed through collaboration between the investigating bodies (Ifakara Health Institute and Swiss Tropical and Public Health Institute), the relevant regulatory authority (Tanzania Food and Drugs Authority) and the manufacturer of AL (Novartis Pharma AG). Training and refresher sessions on the pharmacovigilance system were provided for healthcare workers from local health facilities and field recorders of the Ifakara Health Demographic Surveillance System (IHDSS). Three distinct channels for identification of adverse events (AEs) and serious adverse events (SAEs) were identified and implemented.
Results
Training was provided for 40 healthcare providers (with refresher training 18 months later) and for six field recorders. 
Conclusion
Experience gained in this setting could help to improve spontaneous reporting of AEs and SAEs to health authorities or marketing authorization holders. 
